Intellia Therapeutics
在场
高管
查看带有其 24 名主要高管的组织结构图
Intellia Therapeutics 搜索最多的简介
- John Leonard, President, Chief Executive Officer and Director
- Bill Chase, Director
- Jesse Goodman, Director
高管在Intellia Therapeutics变化
- Glenn Goddard, Executive Vice President and Chief Financial Officer, 将于 20246月29 退休 (新闻发布的2024六月27号).
- Edward DulacEdward Dulac 将于20247月21作为 Executive Vice President, Chief Financial Officer and Treasurer 加入公司 (新闻发布的2024六月27号).
- Brian Goff已作为Director加入公司 (新闻发布的2024六月16号).
创建提醒
跟踪 Intellia Therapeutics 的高管变动
生物技术
Intellia Therapeutics 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Intellia Therapeutics 的最新新闻稿
- Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
- Press Releases - Intellia Therapeutics
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates - Intellia Therapeutics
- Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose - Intellia Therapeutic
- Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 - Intellia Therapeutics
- Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
- Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors - Intellia Therapeutics
- Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference - Intellia Therapeutics
- Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) | Intellia Therapeutics
- Intellia Therapeutics Names John F. Crowley to Board of Directors | Intellia Therapeutics
- View more press releases Close
通过电子邮件
